Symbiotic Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 26-12-2024
- Paid Up Capital ₹ 3.00 M
as on 26-12-2024
- Company Age 24 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 9.50 M
as on 26-12-2024
- Satisfied Charges ₹ 2.20 Cr
as on 26-12-2024
- Revenue 0.94%
(FY 2023)
- Profit -21.26%
(FY 2023)
- Ebitda 9.74%
(FY 2023)
- Net Worth 13.90%
(FY 2023)
- Total Assets 7.35%
(FY 2023)
About Symbiotic Therapeutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 3.00 M.
The company currently has active open charges totaling ₹9.50 M. The company has closed loans amounting to ₹2.20 Cr, as per Ministry of Corporate Affairs (MCA) records.
Bhupender Kaushal and Sanjay Guleria serve as directors at the Company.
- CIN/LLPIN
U51109DL2000PTC106441
- Company No.
106441
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jun 2000
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Symbiotic Therapeutics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhupender Kaushal  | Director | 23-Jun-2000 | Current |
| Sanjay Guleria | Director | 23-Jun-2000 | Current |
Financial Performance of Symbiotic Therapeutics.
Symbiotic Therapeutics Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.94% increase. The company also saw a substantial fall in profitability, with a 21.26% decrease in profit. The company's net worth Soared by an impressive increase of 13.9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Symbiotic Therapeutics?
Unlock access to Symbiotic Therapeutics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Punjab National Bank Creation Date: 20 Apr 2005 | ₹9.50 M | Open |
Others Creation Date: 20 Jun 2019 | ₹2.50 M | Satisfied |
Others Creation Date: 26 Oct 2018 | ₹1.00 M | Satisfied |
How Many Employees Work at Symbiotic Therapeutics?
Symbiotic Therapeutics has a workforce of 144 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Symbiotic Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Symbiotic Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
